Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quantitative EEG for Assessment of Mild Cognitive Impairment Associated With Preclinical Alzheimer's Disease - Evidence for Amyloid Indication Study

NCT03644043 is registered in ClinicalTrials.gov with Metabolic Therapy Inc. as lead sponsor.

NCT NCT03644043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03644043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quantitative EEG for Assessment of Mild Cognitive Impairment Associated With Preclinical Alzheimer's Disease - Evidence for Amyloid Indication Study
Lead sponsor
Metabolic Therapy Inc.
Phase
Observational
Overall status
Unknown status
Start date
July 20, 2018
Completion date
November 30, 2020
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, dementia frontal, mild cognitive impairment